Prevotella intermedia induces matrix metalloproteinase-9 expression in human periodontal ligament cells.
Matrix metalloproteinases (MMPs) play pivotal roles in inflammatory diseases including chronic periodontitis. The effects of Prevotella intermedia, a major periodontal pathogen, on MMP-9 production in primary human periodontal ligament (hPDL) cells were examined in the present study. MMP-9 mRNA expression was measured by semiquantitative reverse transcriptase PCR and its protein secretion was assayed by gelatin zymography. Prevotella intermedia ATCC 25611 supernatant time and dose-dependently induced MMP-9 expression. In contrast, Porphyromanas gingivalis ATCC 33277 supernatants, Escherichia coli lipopolysacchride and IL-1beta exhibited no stimulatory effects on MMP-9 production in hPDL cells. Mitogen-activated protein kinases [MAPK, including extracellular signal-related kinases (ERK), c-jun N-terminal kinases (JNK) and p38] inhibitors exerted no effect on the P. intermedia-induced MMP-9 production, indicating that P. intermedia induced MMP-9 production through an MAPK-independent pathway. Our results demonstrated that P. intermedia may contribute to periodontal tissue destruction during chronic periodontitis by inducing MMP-9 production in hPDL cells.
Guan
Su-Min
SM
Department of Oral Biology, School of Stomatology, The Fourth Military Medical University, Xi'an, China.
Shu
Lei
L
Fu
Shan-Min
SM
Liu
Bin
B
Xu
Xiu-Li
XL
Wu
Jun-Zheng
JZ
D000293:Adolescent; D000873:Anthracenes / Q000494:pharmacology; D016866:Bacteroidaceae Infections / Q000382:microbiology*; D002070:Butadienes / Q000494:pharmacology; D002478:Cells, Cultured; D002648:Child; D017077:Culture Media, Conditioned; D004591:Electrophoresis, Polyacrylamide Gel; D048049:Extracellular Signal-Regulated MAP Kinases / Q000037:antagonists & inhibitors; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology; D053583:Interleukin-1beta / Q000494:pharmacology; D048031:JNK Mitogen-Activated Protein Kinases / Q000037:antagonists & inhibitors; D008070:Lipopolysaccharides / Q000494:pharmacology; D020780:Matrix Metalloproteinase 9 / Q000096:biosynthesis* / Q000378:metabolism; D009570:Nitriles / Q000494:pharmacology; D010513:Periodontal Ligament / Q000201:enzymology* / Q000382:microbiology*; D016966:Porphyromonas gingivalis / Q000472:pathogenicity; D018713:Prevotella intermedia / Q000472:pathogenicity*; D047428:Protein Kinase Inhibitors / Q000494:pharmacology; D011743:Pyrimidines / Q000494:pharmacology; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013997:Time Factors; D048051:p38 Mitogen-Activated Protein Kinases / Q000037:antagonists & inhibitors
D000873:Anthracenes; D002070:Butadienes; D017077:Culture Media, Conditioned; D007093:Imidazoles; D053583:Interleukin-1beta; D008070:Lipopolysaccharides; D009570:Nitriles; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; C113580:U 0126; C432165:pyrazolanthrone; D048049:Extracellular Signal-Regulated MAP Kinases; D048031:JNK Mitogen-Activated Protein Kinases; D048051:p38 Mitogen-Activated Protein Kinases; D020780:Matrix Metalloproteinase 9; C406525:SB 239063